Preserving the Tuft: New Concepts in Glomerular Disease Therapeutics, Including the Michelle P. Winn, MD, Endowed Lectureship
October 22, 2020 | 10:30 AM - 12:30 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
Basic/Clinical Science Session
Preserving the Tuft: New Concepts in Glomerular Disease Therapeutics, Including the Michelle P. Winn, MD, Endowed Lectureship
October 22, 2020 | 10:30 AM - 12:30 PM
Location: Live-Streamed
Session Description
Therapeutic targets for glomerular disease remain scarce, but recent advances bode well for improved patient outcomes and treatment options in the near future. This session explores emerging concepts in the treatment of glomerular disease with a focus on precision-based approaches.
ASN gratefully acknowledges Duke University School of Medicine, the school's Division of Nephrology, and several individuals for support of the Michelle P. Winn, MD, Endowed Lectureship.
Support is provided by an educational grant from Chinook Therapeutics, Inc.
Learning Objective(s)
- Define novel and emerging therapeutic targets for primary glomerular disease
- Describe the specificity, efficacy, and mechanism of action of novel therapeutic agents for glomerular disease
Learning Pathway(s)
Moderators
- Dawn J. Caster, MD, FASN
- Rasheed A. Gbadegesin, MD, MBBS, FASN
Presentations
- Drug Targeting of the Podocyte Actin Cytoskeleton: The Michelle P. Winn, MD, Endowed Lectureship
10:30 AM - 11:00 AM
Mario Schiffer, MD, MBA
Drug Targeting of the Podocyte Actin Cytoskeleton: The Michelle P. Winn, MD, Endowed Lectureship
October 22, 2020 | 10:30 AM - 11:00 AM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Targeting Podocyte Histone Deacetylases
11:00 AM - 11:30 AM
Shuta Ishibe, MD
Shuta Ishibe, MD
My major area of research interest includes 1) the endocytic process in podocytes, 2) cell matrix regulation in podocytes, and 3) therapeutics for glomerular disease. Our laboratory has identified the critical role of the clathrin coated endocytic processes and cell matrix regulation in the development and maintenance of podocytes. We have generated In-vivo animal models with genetic knockout of genes implicated for endocytosis (dynamin ,synaptojanin1, endophilin) and cell matrix (focal adhesion kinase, talin1, vinculin) regulation. Leveraging these knockout mice that develop severe proteinuria, kidney failure, and foot process effacement, has allowed us to identify potential targets for therapeutic interventions (inhibiting histone deacetylase and calpain activation), that may have human applicability, to mitigate the progression of proteinuria induced chronic kidney disease.
Targeting Podocyte Histone Deacetylases
October 22, 2020 | 11:00 AM - 11:30 AM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Therapeutic Targeting of APOL1: Rationale and Current Strategies
11:30 AM - 12:00 PM
Opeyemi A. Olabisi, MD, PhD
Opeyemi A. Olabisi, MD, PhD
Therapeutic Targeting of APOL1: Rationale and Current Strategies
October 22, 2020 | 11:30 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Targeting the Complement System in Glomerular Disease: Novel Concepts
12:00 PM - 12:30 PM
Nicole Van De Kar, MD, PhD
Nicole Van De Kar, MD, PhD
Targeting the Complement System in Glomerular Disease: Novel Concepts
October 22, 2020 | 12:00 PM - 12:30 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
